TP53 Mutations as a Driver of Metastasis Signaling in Advanced Cancer Patients.

ABSTRACT: Molecular profiling with next generation sequencing (NGS) delivers key information on mutant gene sequences, copy number alterations, gene-fusions, and with immunohistochemistry (IHC), is a valuable tool in clinical decision making for patients entering investigational agent trials. Our objective was to elucidate mutational profiles from primary versus metastatic sites from advanced cancer patients to guide rational therapy. All phase I patients (n = 203) with advanced cancer were profiled by commercially available NGS platforms. The samples were annotated by histology, primary and metastatic site, biopsy site, gene mutations, mutation count/gene, and mutant TP53. A molecular profile of each patient was categorized into common and unique mutations, signaling pathways for each

SUBMITTER: Pandey R 

PROVIDER: S-EPMC7913278 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature